Assetmark, Inc Revance Therapeutics, Inc. Transaction History
Assetmark, Inc
- $30.5 Billion
- Q1 2024
A detailed history of Assetmark, Inc transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 68 shares of RVNC stock, worth $174. This represents 0.0% of its overall portfolio holdings.
Number of Shares
68
Previous 2,046
96.68%
Holding current value
$174
Previous $17,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding RVNC
# of Institutions
214Shares Held
83.4MCall Options Held
656KPut Options Held
424K-
Capital World Investors Los Angeles, CA13.9MShares$35.8 Million0.01% of portfolio
-
Black Rock Inc. New York, NY7.31MShares$18.8 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA6.28MShares$16.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.4MShares$13.9 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.25MShares$13.5 Million3.02% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...